HRG-β1 inhibitors are a specialized class of compounds that act by modulating the activity of the HRG-β1 protein, which is involved in a variety of cellular signaling processes. These inhibitors typically function by binding to the HRG-β1 protein or its associated receptors, disrupting its interaction with other proteins or ligands necessary for its normal activity. Structurally, HRG-β1 inhibitors can range from small molecules to larger, more complex compounds such as peptides. The design of these inhibitors often incorporates key functional groups that enable strong binding interactions, such as hydrogen bonds, van der Waals forces, and electrostatic interactions with the target protein or receptor. This binding blocks HRG-β1's ability to engage in its usual role in signal transduction, thereby inhibiting downstream biological processes associated with its activity.
From a chemical perspective, HRG-β1 inhibitors are optimized for stability and selectivity. They are often engineered to resist degradation under various conditions, including enzymatic or oxidative breakdown, which ensures that they retain their inhibitory function in different environments. These compounds also exhibit diverse physical properties, such as solubility and permeability, which are important considerations for their effective interaction with the HRG-β1 target in biological systems. Additionally, the kinetics of HRG-β1 inhibitors can vary, with some showing rapid, reversible binding, while others form more prolonged, potentially irreversible interactions with their target. These characteristics are fine-tuned through careful chemical synthesis and structural modification to achieve the desired inhibitory effect, with the ultimate goal of efficiently disrupting HRG-β1 activity at a molecular level.
| Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
|---|---|---|---|---|---|---|
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $41.00 | 4 | |
Inhibe les enzymes cyclo-oxygénases, affectant potentiellement les voies de l'inflammation et de la coagulation. | ||||||
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $72.00 $162.00 | 7 | |
Inhibe les facteurs de coagulation dépendants de la vitamine K, ce qui peut modifier les voies de coagulation. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $155.00 | 18 | |
Inhibe directement le facteur Xa, affectant probablement la cascade de coagulation liée à la fonction de HRG-β1. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $235.00 $622.00 | 2 | |
inhibiteur du facteur Xa, pourrait modifier la formation de thrombine et affecter les voies de signalisation associées. | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | $120.00 | 1 | |
Inhibe le récepteur P2Y12 de l'ADP sur les plaquettes, ce qui peut avoir un impact sur l'agrégation plaquettaire et les voies connexes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibiteur de tyrosine kinase, pourrait affecter les voies de signalisation cellulaire liées à la croissance et à l'adhésion des cellules. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Inhibe de multiples récepteurs tyrosine kinases, affectant potentiellement l'angiogenèse et la signalisation associée. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Glucocorticoïde qui module l'inflammation, influençant potentiellement les voies de la réponse immunitaire. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Inhibe la dihydrofolate réductase, ce qui peut affecter la prolifération cellulaire et les fonctions immunitaires. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Modifie l'activité immunitaire, affectant probablement les voies liées à l'inflammation et à l'auto-immunité. | ||||||